Cargando…
Single center first year experience and outcomes with Impella 5.5 left ventricular assist device
BACKGROUND: The Impella 5.5® was approved by the FDA for use for mechanical circulatory support up to 14 days in late 2019 at limited centers in the United States. Our single center’s experience with Impella 5.5® can expand the overall understanding for achieving successful patient outcomes as well...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128113/ https://www.ncbi.nlm.nih.gov/pubmed/35606780 http://dx.doi.org/10.1186/s13019-022-01871-1 |